Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients

The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8-10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) regimen versus bortezomib and dexamethasone (VD) regi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hematol Rep
Hlavní autoři: Ciftciler, Rafiye, Goker, Hakan, Buyukasik, Yahya, Sayınalp, Nilgun, Haznedaroglu, Ibrahim C., Aksu, Salih, Ozcebe, Osman, Demiroglu, Haluk
Médium: Artigo
Jazyk:Inglês
Vydáno: PAGEPress Publications, Pavia, Italy 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212206/
https://ncbi.nlm.nih.gov/pubmed/32399162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/hr.2020.8267
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky